CWC Showcases ResQ Biotech’s Platform at Xiamen Innovation Event

On July 28, China West Connector (CWC) proudly presented ResQ Biotech at a high-profile international technology transfer event held in Xiamen Science City, co-organized by ITTN and under the support of the Xiamen Municipal Government. The audience included government officials, university leaders, investors, and international teams from the UK, Italy, Greece, and Hong Kong.

Representing CWC, Ms. Dan Wang delivered an engaging presentation that introduced ResQ Biotech’s pioneering approach to tackling protein misfolding diseases, an area of immense global health significance.

🧬 ResQ Biotech: A Global Leader in Protein Misfolding Therapeutics

Foundation & Mission
Founded in 2019 as a spin-off from the National Hellenic Research Foundation at Patras Science Park, ResQ Biotech is focused on discovering therapeutic candidates for diseases caused by protein misfolding and aggregation, including Alzheimer’s, ALS, systemic amyloidosis, and cancer
Platform Technology
ResQ employs a living microbial discovery platform: engineered E. coli cells biosynthesize and simultaneously screen billions of short cyclic peptides to identify molecules that can correct misfolded proteins. This scalable method allows rapid screening at unprecedented diversity and speed
Scientific Recognition & Publications
- Awarded the Nature Research – Merck Spinoff Prize 2020 as one of the most promising science-based spin-offs in Europe
- Research publications appear in Science Advances and Nature Biomedical Engineering, demonstrating the potency and novelty of ResQ’s cyclic peptide screening platform

📢 Impact of the Presentation

During the forum, Dan Wang presented ResQ Biotech’s platform as a credible and scalable innovation capable of addressing a broad class of debilitating diseases. She emphasized:

The platform’s potential for partnership with pharma and biotech companies looking to expand pipelines with novel cyclic peptide assets.
Possibilities for collaborative research, development, and localization in China’s thriving biotech ecosystem.

CWC’s support showcased ResQ Biotech as a standout European innovator entering the Chinese biotech pipeline, with clear alignment to strategic interests in neurodegenerative and protein-misfolding therapeutics.

🔗 Strategic Value for CWC

This presentation signifies CWC’s commitment to bridging Europe’s cutting-edge biotech startups with China’s innovation platforms. ResQ’s platform fits ideally with Chinese institutional interest in translational medicine, cross-border collaboration, and early-stage drug discovery.

We thank ITTN and Xiamen Science City for the opportunity to present. CWC looks forward to facilitating further dialogue and cooperative ventures around ResQ Biotech’s upcoming initiatives in China’s medical innovation ecosystem.